EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immunosuppressive Microenvironment

Yanan Xu, Xing Liu iD, Boya Xu, Qiuling Li, Luofei Zhang, Cao Li, Zhigang Zhao iD

CNS Neuroscience & Therapeutics · 2026-03 · 32 (3)

DOI: 10.1002/cns.70813 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 07.03.2026. Verfasst von Yanan Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, School of Pharmaceutical Sciences, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Glioma, Tumor Microenvironment, Brain Neoplasms, Sphingomyelin Phosphodiesterase. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Young elite scientist sponsorship program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acid sphingomyelinase (ASM), encoded by SMPD1 , regulates sphingolipid metabolism and has been implicated in tumor progression and immune modulation. However, its role in glioma remains poorly defined.

Methods

We performed a comprehensive analysis of SMPD1 in gliomas using TCGA and CGGA datasets, evaluating its expression patterns, prognostic significance, immune correlations, pathway enrichment, and copy number variation. Using qRT–PCR, we validated in vitro the effect of SMPD1 expression on macrophage polarization. Immunofluorescence staining was used to assess the levels of ASM of clinical samples and its correlation with tumor‐associated macrophages. The functional role of SMPD1 was further validated in vivo.

Results

SMPD1 expression was significantly elevated in high‐grade, IDH‐wildtype, and MGMT‐unmethylated gliomas. High SMPD1 levels were associated with poor prognosis and served as an independent prognostic factor. Tumors with elevated SMPD1 showed increased infiltration of regulatory T cells and M0/M2 macrophages. SMPD1 expression correlated with multiple immune cell markers and immune checkpoint molecules. Cell‐based experiments showed that knocking out or inhibiting ASM drives macrophages toward an M1 phenotype while suppressing M2 polarization. Immunofluorescence analysis confirmed upregulation of ASM protein in high‐grade, IDH‐wildtype gliomas, with a strong positive correlation with CD163 expression in clinical samples. In vivo, inhibition of SMPD1 significantly suppressed glioma growth.

Conclusion

SMPD1 is a potential biomarker and therapeutic target in gliomas. Its upregulation may contribute to the formation of an immunosuppressive microenvironment and promote tumor progression, highlighting its potential relevance in glioma immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaTumor MicroenvironmentBrain NeoplasmsSphingomyelin PhosphodiesteraseBiomarkers, TumorHumansAnimalsPrognosisMiceFemaleMacrophagesCell Line, TumorMale

Stichwörter der Autor:innen

SMPD1acid sphingomyelinasegliomaimmuneprognosistumor microenvironment

Substanzen

Sphingomyelin PhosphodiesteraseBiomarkers, TumorSMPD1 protein, human

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, School of Pharmaceutical Sciences, Capital Medical University, Beijing, China.
  • Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
  • Department of Neurosurgery, Beijing Neurosurgical Institute and Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Xing Liu, Zhigang Zhao

Förderung

  • Young elite scientist sponsorship program

Zitieren

APA

Xu, Y., Liu, X., Xu, B., Li, Q., Zhang, L., Li, C., & Zhao, Z. (2026). SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immunosuppressive Microenvironment. CNS Neuroscience & Therapeutics, 32(3). https://doi.org/10.1002/cns.70813

Vancouver

Xu Y, Liu X, Xu B, Li Q, Zhang L, Li C, et al. SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immunosuppressive Microenvironment. CNS Neuroscience & Therapeutics. 2026;32(3). doi:10.1002/cns.70813

BibTeX
@article{Xu2026,
  author = {Xu, Yanan and Liu, Xing and Xu, Boya and Li, Qiuling and Zhang, Luofei and Li, Cao and Zhao, Zhigang},
  title = {SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immunosuppressive Microenvironment},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  volume = {32},
  number = {3},
  doi = {10.1002/cns.70813}
}
Kostenlos starten →